MCAS

Mast Cell Activation Syndrome (MCAS) is a condition in which Mast Cells are inappropriately activated — firing too easily, too often, or in response to stimuli that shouldn’t trigger them. Unlike Histamine Intolerance, the problem isn’t clearance capacity. The cells themselves are misbehaving.

What Makes It a “Syndrome”

MCAS is defined by three criteria (though the exact formulation is debated — see diagnostic criteria below):

1. Symptoms consistent with mast cell mediator release affecting two or more organ systems
2. Laboratory evidence of mast cell activation (elevated mediators in blood or urine)
3. Response to medications that target mast cell mediators or activation

It’s a syndrome rather than a single disease because it can arise from different underlying causes (see subtypes).

The Three Subtypes

Primary (Clonal) MCAS: The mast cells themselves carry a mutation — most commonly the KIT D816V mutation, which makes the KIT receptor (a tyrosine kinase that regulates mast cell growth and activation) constitutively active. The cell is “stuck on” at a molecular level. This is the same mutation found in systemic mastocytosis, but in MCAS the mast cell numbers are normal — only their behavior is abnormal.

Secondary MCAS: The mast cells are genetically normal but are being chronically activated by an identifiable external trigger — an autoimmune disease, a chronic infection, another inflammatory condition, or a medication. Remove the trigger and the mast cell behavior normalizes (in theory).

Idiopathic MCAS: No clonal mutation is found, and no clear external trigger is identified. The mast cells are overactivating for reasons that current testing can’t explain. This is the largest category and the most contentious. Some researchers believe most “idiopathic” MCAS will eventually be reclassified as one or more identified mechanisms are discovered.

Diagnostic Criteria — The Controversy

Two major sets of diagnostic criteria exist, and they disagree:

Consensus-2 criteria (Valent et al., 2019): Strict. Requires elevated Serum Tryptase (a rise of ≥20% + 2 ng/mL above baseline during a symptomatic episode) as the primary laboratory marker. This set tends to capture more severe or acute presentations but misses chronic, low-grade piecemeal Degranulation where tryptase may not rise.

Consensus-1 / Molderings criteria (Afrin, Molderings et al.): Broader. Accepts a wider range of mediator markers (urine histamine metabolites, prostaglandin D2 metabolites, Heparin, Chromogranin A, leukotriene E4) and does not require tryptase elevation specifically. This set captures more patients, including those with chronic piecemeal degranulation, but critics argue it may over-diagnose.

Why this matters practically

Which criteria your diagnostician uses determines whether you get diagnosed. A patient with clearly elevated urinary prostaglandin D2 metabolites but normal tryptase will be diagnosed under Consensus-1 but not Consensus-2. This isn’t a minor academic disagreement — it affects access to treatment and validation of symptoms.

Why It’s Underdiagnosed

Testing is difficult:

• Mediators are unstable. Histamine has a half-life of minutes in blood. Samples must be chilled immediately and processed on ice. Many labs don’t follow these handling requirements, producing false negatives.
• Baseline tryptase is normal in most MCAS patients (tryptase elevation is more characteristic of mastocytosis).
• 24-Hour Urine Testing is more sensitive but requires proper collection and refrigeration.
• There is no single “MCAS blood test.”
• For a detailed critique of existing diagnostic methods and emerging alternatives, see Existing Diagnostics. The Mast Cell Reactivity Test project is exploring a direct ex vivo measurement approach.

Symptoms mimic other conditions:

• GI symptoms → diagnosed as IBS
• Tachycardia and flushing → diagnosed as anxiety or panic disorder
• Fatigue and brain fog → attributed to depression or stress
• Skin reactions → attributed to eczema or “sensitive skin”
• Multiple seemingly unrelated symptoms → patient labeled as “complex” or “somatizing”

Gender disparity: MCAS appears to be more common in women (possibly due to estrogen-mast cell interactions), and women’s multi-system complaints are more likely to be dismissed as psychosomatic. Perimenopause (see Estrogen and Mast Cells) can dramatically amplify previously subclinical MCAS, and these symptoms are often attributed to “just menopause” or anxiety.

ASD-related underdiagnosis: People with ASD may report symptoms differently (atypical descriptions of sensations, difficulty with interoception), may mask symptoms, and may be dismissed by providers who attribute physical complaints to “behavioral issues.” See ASD and Mast Cells.

Prevalence

Estimates vary widely depending on diagnostic criteria used. Conservative estimates suggest 1-5% of the population may have some form of MCAS. Afrin and colleagues have proposed that MCAS may affect up to 17% of the population when broader criteria are applied, though this figure is debated.

Key Connections

• HIT vs MCAS — distinguishing enzyme deficiency from cell misbehavior
• The Trifecta — MCAS, POTS, and EDS — the common comorbid pattern
• Symptom Mapping — how specific mediators produce specific symptoms
• Medications Overview — biochemical targets for intervention
• Total Mediator Load — the framework for understanding variable reactivity
• Intervention Targets — the full therapeutic target landscape